



GIG
CYMRU
NHS
WALES

Bwrdd Iechyd Prifysgol
Bae Abertawe
Swansea Bay University
Health Board

Cadeirydd/Chair: **Emma Woollett**
Prif Weithredwr/Chief Executive: **Tracy Myhill**

gofalu am ein gilydd, cydweithio, gwella bob amser
caring for each other, working together, always improving

Rydym yn croesawu gohebiaeth yn y Gymraeg ac yn y Saesneg. We welcome correspondence in Welsh or English.

Dyddiad/Date: 27th July 2020
Ein Cyf / Our Ref: 20-E-017

☎ 01639 648363

✉ FOIA.Requests@wales.nhs.uk

Corporate Services
Headquarters
1 Talbot Gateway
Baglan
Port Talbot, SA12 7BR

Dear

I refer to your Freedom of Information Act Request acknowledged by ourselves on 20th May 2020. Your request sought information relating to head and neck cancer.

Please note that the information we have provided is for the period 01.11.29 – 30.04.20.

1. Within your health board how many patients have been treated in the past 6 months for head and neck cancer (Squamous cell carcinoma)?

The number of patients currently being treated is not held centrally. Information can only be provided for patients at point of presentation but not at any other point in their pathway. To obtain this information would involve a manual trawl and search of records which we have estimated would significantly exceed the 18 hours limit set down by the FOI Act as the reasonable limit. Section 12 of the FOI Act provides that we are not obliged to spend in excess of 18 hours in any sixty day period locating, retrieving and identifying information in order to deal with a request for information and therefore we are withholding this information at this time.

2. Of these patients how many are locally advanced, recurrent, metastatic and unresectable head and neck cancer patients?

See question 1.

3. Within your health board how many patients have been treated in the past 6 months for head and neck cancer (Squamous cell carcinoma) with the following agents?

Carboplatin (only or in combination with 5-FU) - 7



Pencadlys BIP Bae Abertawe, Un Porthfa Talbot, Port Talbot, SA12 7BR / Swansea Bay UHB Headquarters, One Talbot Gateway, Port Talbot, SA12 7BR

Bwrdd Iechyd Prifysgol Bae Abertawe yw enw gweithredu Bwrdd Iechyd Lleol Prifysgol Bae Abertawe
Swansea Bay University Health Board is the operational name of Swansea Bay University Local Health Board

Cisplatin (only or in combination with 5-FU) - 28

Cetuximab with/without chemotherapy - 0

Cetuximab with radiotherapy - <5

Pembrolizumab monotherapy - 0

Pembrolizumab with chemotherapy - 0

Nivolumab - <5

Docetaxel (only or in combination with 5-FU) - 0

Fluorouracil (5FU) - 0

Radiotherapy only - The number of patients is not held centrally. To obtain this information would involve a manual trawl and search of records which we have estimated would significantly exceed the 18 hours limit set down by the FOI Act as the reasonable limit. Section 12 of the FOI Act provides that we are not obliged to spend in excess of 18 hours in any sixty day period locating, retrieving and identifying information in order to deal with a request for information and therefore we are withholding this information at this time.

Other - 0

Does your health board participate in any ongoing clinical trials for the treatment of head and neck cancer patients, if so how many patients are currently taking part in clinical trials / what is the name/s of the trials?

Yes I can confirm the Health Board does participate in trials and these are listed below:

- CompARE: Phase III randomised controlled trial comparing alternative regimens for escalating treatment of intermediate and high-risk oropharyngeal cancer
- NIMRAD: A randomised placebo-controlled trial of synchronous NIMorazole versus RADiotherapy alone in patients with locally advanced head and neck squamous cell carcinoma not suitable for synchronous chemotherapy or Cetuximab
- PATHOS: A Phase III trial of risk-stratified, reduced intensity adjuvant treatment in patients undergoing transoral surgery for Human Papillomavirus (HPV)-positive oropharyngeal cancer (Post-operative adjuvant treatment for HPV-positive tumours)

There are 18 patients recruited to the above trials.

4. Within your health board how many patients have been treated in the past 6 months with the following agent for colorectal cancer [CRC];

Aflibercept - 0

Bevacizumab - <5

Capecitabine - 34

CAPIRI - 7



CAPOX - 78

Cetuximab not in combination with FOLFIRI or FOLFOX - <5

Cetuximab in combination with FOLFIRI - 7

Cetuximab in combination with FOLFOX - <5

Irinotecan - <5

FOLFIRI - 20

FOLFOX - 12

Oxaliplatin - 0

Panitumumab not in combination with FOLFIRI or FOLFOX - <5

Panitumumab in combination with FOLFIRI - <5

Panitumumab in combination with FOLFOX - <5

Nivolumab - 0

Raltitrexed - 0

Ramucirumab - 0

Regorafenib - <5

Sorafenib - 0

5FU only - 5

Tegafur Uracil + 5FU - 0

Trifluridine–tipiracil - 11

XELOX - As above

Other - 26

5. Within your health board how many patients have been treated in the past 6 months with the following agent for Renal Cell Carcinoma:

Sunitinib - <5

Avelumab + Axitinib - 0

Axinitib - <5

Cabozantinib - 16

Everolimus - 0

Lenvantinib + Everolimus - 8

Nivolumab - 18

Nivolumab + Ipilimumab - 11

Pazopanib - 23

Pembrolizumab + Axitinib - 0



Sunitinib - As above

Temsirolimus - 0

Tivozanib - 12

Does your health board participate in any ongoing clinical trials for the treatment of renal cell cancer patients, if so how many patients are currently taking part in clinical trials / what is the name/s of the trials?

Yes I can confirm the Health Board does participate in trials and these are listed below:

- A Phase 3 Randomized Study Comparing Nivolumab and Ipilimumab Combination vs Placebo in Participants with Localized Renal Cell Carcinoma Who Underwent Radical or Partial Nephrectomy and Who Are at High Risk of Relapse
- A Randomized, Double-blind, Phase 2 Trial to Assess Safety and Efficacy of Lenvatinib at Two Different Starting Doses (18 mg vs. 14 mg QD) in Combination with Everolimus (5 mg QD) in Renal Cell Carcinoma Following One Prior VEGF-Targeted Treatment
- A Phase 3, Randomized, Open-Label Study of Nivolumab Combined with Ipilimumab Versus Sunitinib Monotherapy in Subjects with Previously Untreated, Advanced or Metastatic Renal Cell Carcinoma
- A Phase 3, Multicenter, Randomized, Placebo-Controlled, Double-blind Study of Atezolizumab (Anti-PD-L1 Antibody) as Adjuvant Therapy in Patients with PD-L1-Selected Renal Cell Carcinoma at Intermediate to High Risk of Developing Metastasis Following Nephrectomy
- A Phase 3, open-label, randomized study of Atezolizumab (Anti PD-L1 antibody) in combination with Bevacizumab versus Sunitinib in patients with untreated advanced renal cell carcinoma

There are 37 patients recruited to the above trials.

I hope this information is helpful. If you require anything further please contact us at FOIA.Requests@wales.nhs.uk.

Under the terms of the Health Board's Freedom of Information policy, individuals seeking access to recorded information held by the Health Board are entitled to request internal review of the handling of their requests. If you would like to complain about the Health Board's handling of your request please contact me directly at the address below or register your complaint via FOIA.Requests@wales.nhs.uk.

If after Internal Review you remain dissatisfied you are also entitled to refer the matter to the information commissioner at the Information Commissioner's Office (Wales), 2nd Floor, Churchill House, Churchill Way, Cardiff, CF10 2HH. Telephone Number: 029 2067 8400.



Yours sincerely



Pam Wenger
Director of Corporate Governance

